都梁软胶囊与阿罗洛尔联合防治偏头痛的临床观察

目的：探讨都梁软胶囊联合阿罗洛尔防治偏头痛的疗效。方法：将101例临床确诊为偏头痛的患者以随机抽样法分为2组，都梁软胶囊联合阿罗洛尔组（观察组）51例，阿罗洛尔组（对照组）50例。观察组给予都梁软胶囊1次3粒，1日3次，口服；阿罗洛尔10mg，1日1次，口服。对照组给予阿罗洛尔10mg，1日1次，口服。2组患者均连续治疗12周，并随访3个月，比较2组患者治疗前后头痛发作频次、严重程度、持续时间以及不良反应情况。结果：观察组患者头痛发作频次、严重程度和持续时间均明显减少，与对照组比较差异有统计学意义（P〈0．05），且不良反应少。结论：都梁软胶囊联合阿罗洛尔可改善慢性偏头痛患者的头痛发作程度，减少头痛的持续时间，值得临床推广应用。

Clinical Observation on Duliang Soft Capsules in Combination with Arotinolol for Prevention and Treatment of Migraine

OBJECTIVE：To evaluate the efficacy of Duliang soft capsules in combination with Arotinolol in theprevention and treatment of migraine. METHODS： Patients diagnosed as having migraine were randomly assigned to receive Duliang soft capsules （ one capsule/time t. i. d orally） in combination with Arotinolol （ 10 mg q. d orally） （observation group） or Arotinolol （10 mg q. d orally） alone （control group） for 12 weeks. The patients were followed- up for 3 months, with the two groups compared with regard to frequency, severity and duration of migraine attack and adverse drug reactions before and after treatment. RESULTS： The frequency, severity and duration of migraine attack were significantly reduced in the observation group, showing statistically control group （ P 〈 0.05 ）. CONCLUSION ： Duliang soft capsules in severity and duration of the attack of chronic migraine hence the therapy significant differences as compared with the combination with Arotinolol can reduce the is worthy of clinical popularization.